Merck announced on Monday that a Phase III clinical trial had met its primary endpoint in patients with pulmonary arterial hypertension.

The pharmaceutical group explains that the study involved individuals with functional class (FC) III or IV pulmonary arterial hypertension (PAH) at high risk of mortality according to the World Health Organization (WHO).

In the study, Winrevair demonstrated a 'statistically significant' and 'clinically relevant' reduction in the risk of morbidity or mortality compared with placebo.

Based on these results, the independent study monitoring committee recommended that the trial be stopped prematurely, and that all participants be offered access to Winrevair.

Copyright (c) 2024 CercleFinance.com. All rights reserved.